Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Free Cash Flow (2021 - 2025)

ARS Pharmaceuticals' Free Cash Flow history spans 5 years, with the latest figure at -$43.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 204.71% year-over-year to -$43.5 million; the TTM value through Dec 2025 reached -$171.2 million, down 1418.48%, while the annual FY2025 figure was -$171.2 million, 1418.48% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$43.5 million at ARS Pharmaceuticals, down from -$41.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $41.5 million in Q4 2024 and bottomed at -$45.4 million in Q2 2025.
  • The 5-year median for Free Cash Flow is -$13.7 million (2023), against an average of -$13.8 million.
  • The largest annual shift saw Free Cash Flow soared 337.45% in 2024 before it plummeted 530.36% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $28.7 million in 2021, then plummeted by 171.83% to -$20.6 million in 2022, then rose by 15.05% to -$17.5 million in 2023, then surged by 337.45% to $41.5 million in 2024, then crashed by 204.71% to -$43.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Free Cash Flow are -$43.5 million (Q4 2025), -$41.5 million (Q3 2025), and -$45.4 million (Q2 2025).